China Accepts Chugai's NDA Submission for Novel Osteoporosis Treatment

Chugai Pharma reported that the CFDA accepted its New Drug Application for eldecalcitol, an oral active vitamin D3 derivative for osteoporosis. A Japanese pharma, Chugai is majority-owned (62%) by Roche. In a China Phase III trial, patients treated with eldecalcitol showed greater bone mineral density (BMD) compared to alfacalcidol-treated patients after 12 months. Chugai has marketed eldecalcitol in Japan since 2011. More details.... Stock Symbols: (TYO: 4519) (ROG: SIX) Share this with colleagues: // //